![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Tokyo, Japan (H.H., M.T., H.J.S., E.B., P.J., S.K., M.A., N.A., H.E.); Department of Clinical Preventive Medicine, Nagoya University School of Medicine, Nagoya, Japan (K.T., A.E., T.N.); Department of Nephrology and Endocrinology, University of Tokyo, Tokyo, Japan (M.L.O., A.T.); and Kobuchizawa Laboratories, Fuji Biomedixs Co., Yamanashi, Japan (S.N., X.-L.H.)
The tubular secretion of diuretics in the proximal tubule has been shown to be critical for the action of drugs. To elucidate the molecular mechanisms for the tubular excretion of diuretics, we have elucidated the interactions of human organic anion transporters (hOATs) with diuretics using cells stably expressing hOATs. Diuretics tested were thiazides, including chlorothiazide, cyclothiazide, hydrochlorothiazide, and trichlormethiazide; loop diuretics, including bumetanide, ethacrynic acid, and furosemide; and carbonic anhydrase inhibitors, including acetazolamide and methazolamide. These diuretics inhibited organic anion uptake mediated by hOAT1, hOAT2, hOAT3, and hOAT4 in a competitive manner. hOAT1 exhibited the highest affinity interactions for thiazides, whereas hOAT3 did those for loop diuretics. hOAT1, hOAT3, and hOAT4 but not hOAT2, mediated the uptake of bumetanide. hOAT3 and hOAT4, but not hOAT1 mediated the efflux of bumetanide. hOAT1 and hOAT3, but not hOAT2 and hOAT4 mediated the uptake of furosemide. In conclusion, it was suggested that hOAT1 may play an important role in the basolateral uptake of thiazides, and hOAT3 in the uptake of loop diuretics. In addition, it was also suggested that bumetanide taken up by hOAT3 and/or hOAT1 is excreted into the urine by hOAT4.
Address correspondence to: Dr. Hitoshi Endou, Department of Pharmacology and Toxicology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan. E-mail: endouh{at}kyorin-u.ac.jp
This article has been cited by other articles:
![]() |
A. Bahn, Y. Hagos, S. Reuter, D. Balen, H. Brzica, W. Krick, B. C. Burckhardt, I. Sabolic, and G. Burckhardt Identification of a New Urate and High Affinity Nicotinate Transporter, hOAT10 (SLC22A13) J. Biol. Chem., June 13, 2008; 283(24): 16332 - 16341. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Vallon, T. Rieg, S. Y. Ahn, W. Wu, S. A. Eraly, and S. K. Nigam Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics Am J Physiol Renal Physiol, April 1, 2008; 294(4): F867 - F873. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hagos, A. Bahn, S. V. Vormfelde, J. Brockmoller, and G. Burckhardt Torasemide Transport by Organic Anion Transporters Contributes to Hyperuricemia J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3101 - 3109. [Full Text] [PDF] |
||||
![]() |
N. Mizuno, T. Takahashi, Y. Iwase, H. Kusuhara, T. Niwa, and Y. Sugiyama Human Organic Anion Transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) Transport Edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and Its Sulfate Conjugate Drug Metab. Dispos., August 1, 2007; 35(8): 1429 - 1434. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ueo, H. Motohashi, T. Katsura, and K.-i. Inui Cl--dependent upregulation of human organic anion transporters: different effects on transport kinetics between hOAT1 and hOAT3 Am J Physiol Renal Physiol, July 1, 2007; 293(1): F391 - F397. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nozaki, H. Kusuhara, T. Kondo, M. Hasegawa, Y. Shiroyanagi, H. Nakazawa, T. Okano, and Y. Sugiyama Characterization of the Uptake of Organic Anion Transporter (OAT) 1 and OAT3 Substrates by Human Kidney Slices J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 362 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hagos, D. Stein, B. Ugele, G. Burckhardt, and A. Bahn Human Renal Organic Anion Transporter 4 Operates as an Asymmetric Urate Transporter J. Am. Soc. Nephrol., February 1, 2007; 18(2): 430 - 439. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hasegawa, H. Kusuhara, M. Adachi, J. D. Schuetz, K. Takeuchi, and Y. Sugiyama Multidrug Resistance-Associated Protein 4 Is Involved in the Urinary Excretion of Hydrochlorothiazide and Furosemide J. Am. Soc. Nephrol., January 1, 2007; 18(1): 37 - 45. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Murakami, N. Kohyama, Y. Kobayashi, M. Ohbayashi, H. Ohtani, Y. Sawada, and T. Yamamoto FUNCTIONAL CHARACTERIZATION OF HUMAN MONOCARBOXYLATE TRANSPORTER 6 (SLC16A5) Drug Metab. Dispos., December 1, 2005; 33(12): 1845 - 1851. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tahara, H. Kusuhara, H. Endou, H. Koepsell, T. Imaoka, E. Fuse, and Y. Sugiyama A Species Difference in the Transport Activities of H2 Receptor Antagonists by Rat and Human Renal Organic Anion and Cation Transporters J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 337 - 345. [Abstract] [Full Text] [PDF] |
||||